Literature DB >> 24671471

The role of the pathologist in the diagnosis and treatment of dysplasia in inflammatory bowel disease.

Mariana Berho1, Daniela Allende.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24671471     DOI: 10.1007/s11605-014-2505-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


× No keyword cloud information.
  5 in total

1.  Variability in the diagnosis of dysplasia in ulcerative colitis by dynamic telepathology.

Authors:  Robert D Odze; John E Tomaszewski; Emma E Furth; Michael D Feldman; Raihanatou Diallo; Christopher Poremba; Ingrid Becker; Heinz Hoefler; John R Goldblum; Lisa A Rybicki; Nada Alsaigh; Franz Fogt
Journal:  Oncol Rep       Date:  2006-11       Impact factor: 3.906

2.  Inflammatory bowel disease as a risk factor for colorectal cancer.

Authors:  Milan Lukas
Journal:  Dig Dis       Date:  2010-11-18       Impact factor: 2.404

3.  Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology.

Authors:  Robert D Odze; John Goldblum; Amy Noffsinger; Nada Alsaigh; Lyndo A Rybicki; Franz Fogt
Journal:  Mod Pathol       Date:  2002-04       Impact factor: 7.842

Review 4.  Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis.

Authors:  T Thomas; K A Abrams; R J Robinson; J F Mayberry
Journal:  Aliment Pharmacol Ther       Date:  2007-03-15       Impact factor: 8.171

Review 5.  Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies.

Authors:  John K Triantafillidis; Georgios Nasioulas; Paris A Kosmidis
Journal:  Anticancer Res       Date:  2009-07       Impact factor: 2.480

  5 in total
  1 in total

Review 1.  Endoscopic detection and resection of dysplasia in inflammatory bowel disease-techniques with videos.

Authors:  Sameen Khalid; Aamer Abbass; Neelam Khetpal; Bo Shen; Udayakumar Navaneethan
Journal:  Int J Colorectal Dis       Date:  2019-03-11       Impact factor: 2.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.